| abstract |
The invention discloses the medicinal preparation and application of rosmarinic acid or a derivative thereof as a novel TRPC1 antagonist. We found that rosmarinic acid has an antagonistic effect on the TRPC1 channel, and thus has a significant inhibitory effect on myocardial ischemia-reperfusion injury and atherosclerosis, and can be used to prevent or treat myocardial ischemia-reperfusion injury diseases, atherosclerosis Sclerosis disease, atrial fibrillation disease, epilepsy disease, sepsis disease, atherosclerotic disease, osteoporosis disease. The medicine takes rosmarinic acid, rosmarinic acid derivatives and their salts or their solvates as the single active ingredient or as one of the active ingredients, and can take tablets, capsules, granules, pills, powders, injections and Pharmaceutically acceptable dosage forms such as powder injection. |